VANCOCIN HYDROCHLORIDE Drug Patent Profile

Which patents cover Vancocin Hydrochloride, and what generic alternatives are available?

Vancocin Hydrochloride is a drug marketed by Ani Pharms and Steriscience and is included in six NDAs.

The generic ingredient in VANCOCIN HYDROCHLORIDE is vancomycin hydrochloride. There are twenty-two drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the vancomycin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vancocin Hydrochloride

A generic version of VANCOCIN HYDROCHLORIDE was approved as vancomycin hydrochloride by FRESENIUS KABI USA on March 17^th, 1987.

Summary for VANCOCIN HYDROCHLORIDE

US Patents:	0
Applicants:	2
NDAs:	6
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	50
Clinical Trials:	35
DailyMed Link:	VANCOCIN HYDROCHLORIDE at DailyMed

Recent Clinical Trials for VANCOCIN HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute of Allergy and Infectious Diseases (NIAID)	Phase 4
Alexander Flannery	Phase 4
Memorial University of Newfoundland	Phase 3

See all VANCOCIN HYDROCHLORIDE clinical trials

Pharmacology for VANCOCIN HYDROCHLORIDE

Drug Class

Glycopeptide Antibacterial

US Patents and Regulatory Information for VANCOCIN HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ani Pharms	VANCOCIN HYDROCHLORIDE	vancomycin hydrochloride	CAPSULE;ORAL	050606-001	Apr 15, 1986	AB	RX	Yes	No
Steriscience	VANCOCIN HYDROCHLORIDE	vancomycin hydrochloride	INJECTABLE;INJECTION	062716-002	Mar 13, 1987		DISCN	No	No
Ani Pharms	VANCOCIN HYDROCHLORIDE	vancomycin hydrochloride	FOR SOLUTION;ORAL	061667-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Steriscience	VANCOCIN HYDROCHLORIDE	vancomycin hydrochloride	INJECTABLE;INJECTION	062716-001	Mar 13, 1987		DISCN	No	No
Steriscience	VANCOCIN HYDROCHLORIDE	vancomycin hydrochloride	INJECTABLE;INJECTION	062812-002	Nov 17, 1987		DISCN	No	No

Market Dynamics and Financial Trajectory for Vancomycin Hydrochloride

Last updated: February 8, 2026

Market Overview

Vancomycin hydrochloride is a glycopeptide antibiotic primarily used to treat severe bacterial infections caused by gram-positive bacteria, notably methicillin-resistant Staphylococcus aureus (MRSA). Its significance stems from its efficacy against resistant strains, positioning it as a critical option in hospital and antimicrobial stewardship settings.

Market Size and Growth

The global vancomycin market was valued at approximately $400 million in 2022 and is projected to grow at a compound annual growth rate (CAGR) of around 4.8% through 2030. The growth drivers include rising antibiotic resistance, increasing hospital-acquired infections, and expanding global healthcare infrastructure.

Key Market Drivers

• Antibiotic Resistance: The escalation of MRSA and other resistant bacteria cases increases demand for vancomycin as a first-line treatment.
• Healthcare-Associated Infections (HAIs): The rising incidence of HAIs compels hospitals to stock potent antibiotics like vancomycin.
• Regulatory Approvals: Approvals for generic versions and new formulations expand market access and volume.

Market Challenges

• Antimicrobial Stewardship Restrictions: Growing emphasis on responsible antibiotic use limits unnecessary prescriptions, potentially constraining volume growth.
• Emerging Resistance: Although vancomycin remains effective against most strains, reports of vancomycin-resistant enterococci (VRE) and strains of VRSA (vancomycin-resistant S. aureus) threaten long-term utility.
• Pricing Pressures: Payer negotiations and governmental pricing policies exert downward pressure on profit margins.

Supply Chain and Manufacturing

Vancomycin production is complex, involving fermentation of proprietary microorganisms (e.g., Amycolatopsis orientalis). The market features both brand-name (Vancocin) and generic manufacturers. Major firms include Merck & Co. (Vancocin) and multiple generics producers in India, China, and Europe.

Financial Trajectory

• Revenue Trends: Major pharmaceutical companies report stable revenues from vancomycin, with small but consistent growth driven by generic expansion.
• Profitability: Margins for generic producers depend on manufacturing costs, with recent trends favoring price reductions due to competition.
• R&D Investment: Limited R&D focuses on new formulations or delivery mechanisms rather than novel compounds, constraining transformative innovation.

Pricing and Reimbursement

• Pricing Trends: Increased generic competition has driven prices down. In the US, retail prices for a 1-gram vial have declined from approximately $50 in 2015 to around $25 in 2022.
• Reimbursement Policies: Medicare and Medicaid reimbursements influence pricing strategies. Increased use of biosimilars and generics typically reduces reimbursement rates.

Regulatory Environment

The FDA continues to monitor resistance developments. Approval pathways for generic versions under ANDA (Abbreviated New Drug Application) streamline entry, increasing competitive pressure.

Future Outlook

• The market is expected to grow moderately at 4-5% CAGR through 2030.
• Innovation efforts will likely focus on optimizing delivery, reducing toxicity, or developing novel formulations.
• Resistance trends could influence market stability, incentivizing stewardship programs to limit overuse.

Key Takeaways

• The vancomycin market hinges on antimicrobial resistance patterns and healthcare infection rates.
• Growth is steady but constrained by resistance and stewardship policies.
• Price erosion from generic competition remains a dominant financial factor.
• Limited R&D signals a focus on improving existing formulations rather than new drugs.
• Long-term demand sustainability depends on resistance development and clinical guidelines.

FAQs

1. How does antimicrobial resistance impact vancomycin's market?
   Resistant bacteria strains diminish vancomycin's effectiveness, potentially reducing demand and prompting shifts toward novel agents or combination therapies.

2. What are the main competitors in the vancomycin market?
   Primary competitors include Merck with Vancocin and various generic manufacturers in India, China, and Europe.

3. How are pricing trends affecting profitability?
   Price reductions driven by competition have lowered margins, especially in markets dominated by generics.

4. Are there emerging alternatives to vancomycin?
   Yes, newer agents like televancin and linezolid are options, but vancomycin remains a first-line agent for many resistant infections.

5. Will resistance development threaten long-term demand?
   Yes, increased resistance could limit vancomycin’s effectiveness, emphasizing the need for stewardship and new antimicrobial development.

References

[1] MarketWatch, "Global Vancomycin Market Size, Share & Trends Analysis Report by Application," 2022.
[2] Persistence Market Research, "Vancomycin Market Forecast," 2023.
[3] U.S. Food and Drug Administration (FDA), "Drug Approvals and Resistance Monitoring," 2023.
[4] IQVIA, "Healthcare Data and Pricing Trends," 2022.